GlassScriptPhysician profile
Yasemin Sozeri
NPI 1215343827
$1,813.05
in general payments reported to CMS, 2019-2025
11 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $181 · 2021: $122 · 2022: $37.90 · 2023: $714 · 2024: $115 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $557.15 | 2023-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Allergan, INC. | $286.78 | 2019-2021 | |
| Sight Sciences, INC. | $239.56 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Nova Eye, INC. | $206.15 | 2023 | |
| Alcon Vision LLC | $199.84 | 2022-2025 | Centurion, Hydrus Microstent, Clareon |
| Abbvie INC. | $112.01 | 2022-2025 | Durysta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.98 | 2019 | |
| Aerie Pharmaceuticals, INC. | $40.83 | 2019 | |
| Ocular Therapeutix, INC. | $29.73 | 2021 | |
| Halozyme INC | $21.66 | 2024 | Hylenex Recombinant |
| Sun Pharmaceutical Industries INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasemin Sozeri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.